The global pancreatic cancer treatment market value in the six major countries (U.S., France, Germany, Italy, Spain and the UK) will increase from $529 million in 2012 to $1.63 billion by 2017.
The global pancreatic cancer treatment market value in the six major countries (U.S., France, Germany, Italy, Spain and the UK) will increase from $529 million in 2012 to $1.63 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 25.2%, says a new report from GlobalData (London, UK).
According to the report, the U.S. will show the most growth in the pancreatic cancer therapeutics market, with its total value jumping from $275 million in 2012 to $1.17 billion by 2017, at a higher CAGR of 33.5%. This will be followed by the five European countries, with their combined market values expected to increase from $254 million in 2012 to $463 million by 2017, (CAGR 12.8%).
Savade Solanki, GlobalData’s Associate Director of Oncology, says that this rapid market expansion is due to the launch of Celgene’s Abraxane in the U.S. and Europe in 2013 and 2014, respectively, along with the incorporation of five pipeline agents into U.S. clinical practice.
Sales of Abraxane are expected to undergo “a massive rise, from $21 million (off-label) in 2012 to $954 million in 2017, at a CAGR of 115%”, says GlobalData. The drug will represent nearly 60% of the pancreatic cancer therapeutics market by the end of the forecast period.
Of the five upcoming pipeline agents, “NewLink Genetics Corporation’s algenpantucel-L is expected to garner the highest sales,” says Solanki. “Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck’s TH-302 and Merrimack Pharmaceuticals’ MM-398.”
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.